Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium-177-labeled control liposomes
- Development stage
- Preclinical
- Lead developer
- University of Virginia
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**Lutetium-177-labeled control liposomes** are non-targeted, DTPA-chelated liposomal radiopharmaceutical research constructs developed as comparator particles for targeted lutetium-177 immunoliposomes in malignant mesothelioma models. The formulation contains phospholipids, cholesterol, PEGylated lipid, and DMPE-DTPA, with lutetium-177 chelated to the DTPA-containing lipid. Unlike the CD24/CD26-targeted immunoliposomes studied alongside it, this control construct has no antibody-based tumor-targeting ligand; its antitumor activity is mediated by beta-particle radiation emitted by lutetium-177 after cellular or passive tumor-associated liposome exposure. In vitro, it showed cytotoxic and pro-apoptotic activity against mesothelioma cells, but was less effective than CD24/CD26-targeted lutetium-177 immunoliposomes. ([mdpi.com](https://www.mdpi.com/1422-0067/23/7/3914))
- Other names
- 177Lu-CL177Lu-CLs177Lu-labeled CLs177Lu-labeled control liposome177Lu-labeled control liposomes
Beyond the preview
Go deeper on lutetium-177-labeled control liposomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium-177-labeled control liposomes.